NASDAQ:OPGN - OpGen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.78 -0.01 (-0.56 %)
(As of 08/19/2018 12:55 PM ET)
Previous Close$1.78
Today's Range$1.77 - $1.84
52-Week Range$1.62 - $10.25
Volume68,759 shs
Average Volume380,018 shs
Market Capitalization$10.99 million
P/E Ratio-0.18
Dividend YieldN/A
Beta1.5
OpGen logoOpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPGN
CUSIPN/A
Phone240-813-1260

Debt

Debt-to-Equity Ratio0.19
Current Ratio2.13
Quick Ratio1.99

Price-To-Earnings

Trailing P/E Ratio-0.18
Forward P/E Ratio-0.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.21 million
Price / Sales3.44
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book2.87

Profitability

EPS (Most Recent Fiscal Year)($9.78)
Net Income$-15,410,000.00
Net Margins-373.39%
Return on Equity-261.32%
Return on Assets-124.09%

Miscellaneous

Employees43
Outstanding Shares6,210,000
Market Cap$10.99 million

OpGen (NASDAQ:OPGN) Frequently Asked Questions

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

When did OpGen's stock split? How did OpGen's stock split work?

OpGen shares reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

How were OpGen's earnings last quarter?

OpGen Inc (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, August, 2nd. The medical research company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.03. The medical research company earned $0.79 million during the quarter, compared to analyst estimates of $0.79 million. OpGen had a negative return on equity of 261.32% and a negative net margin of 373.39%. View OpGen's Earnings History.

When is OpGen's next earnings date?

OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for OpGen.

What price target have analysts set for OPGN?

1 analysts have issued 1-year price targets for OpGen's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate OpGen's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 349.4% from the stock's current price. View Analyst Price Targets for OpGen.

What is the consensus analysts' recommendation for OpGen?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.

Who are some of OpGen's key competitors?

Who are OpGen's key executives?

OpGen's management team includes the folowing people:
  • Mr. Evan Jones, Chairman & CEO (Age 61)
  • Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 59)
  • Mr. Vadim Sapiro, Chief Information Officer (Age 47)
  • Mr. Michael Farmer, VP of Marketing
  • Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 59)

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

Has OpGen been receiving favorable news coverage?

Press coverage about OPGN stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OpGen earned a coverage optimism score of 0.12 on Accern's scale. They also assigned headlines about the medical research company an impact score of 48.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for OpGen.

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include B. Riley Financial Inc. (2.22%) and Acadian Asset Management LLC (0.99%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.

Which major investors are buying OpGen stock?

OPGN stock was bought by a variety of institutional investors in the last quarter, including B. Riley Financial Inc. and Acadian Asset Management LLC. Company insiders that have bought OpGen stock in the last two years include Jven Capital, Llc and Timothy C Dec. View Insider Buying and Selling for OpGen.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $1.78.

How big of a company is OpGen?

OpGen has a market capitalization of $10.99 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]


MarketBeat Community Rating for OpGen (NASDAQ OPGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.